Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 nov. 2025 12h03 HE | Source: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative...
07 janv. 2025 08h00 HE | Source: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis

* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate *...
09 juil. 2024 08h30 HE | Source: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Issues Letter to Shareholders

Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently...